Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease

British Journal of Ophthalmology

Volumn 80, Issue 11, 1996, Pages 1002-1008

  Norose, Kazumi ^a   Yano, Akihiko ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; T LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CHROMIUM 51 RELEASE; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; PRIORITY JOURNAL; VOGT KOYANAGI SYNDROME;

EID: 0029803602     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.80.11.1002     Document Type: Article

References (38)

1. Norose K, Yano A, Wang X-c, Tokushima T, Umihira J, Seki A, et al. Dominance of activated T cells and interleukin-6 in aqueous humor in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1994;35:33-9.
2. Sakamoto T, Murata T, Inomata H. Class II major histocompatibility complex on melanocytes of Vogt-Koyanagi-Harada disease. Arch Ophthalmol 1991;109:1270-4.
3. Norose K, Yano A, Aosai F, Segawa K. Immunologic analysis of cerebrospinal fluid lymphocytes in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci 1990;31:1210-6.
4. De Vos AF, Hoekzema R, Kijlstra A. Cytokines and uveitis, a review. Curr Eye Res 1992;11:581-97.
5. Romagnani S. Human TH1 and TH2 subsets: regulation of differentiation and role in protection and immunopathology. Int Arch Allergy Immunol 1992;98:279-85.
6. Paul WE, Sredni B, Schwartz RH. Long-term growth and cloning of non-transformed lymphocytes. Nature 1981;294:697-9.
7. Smith KA. Interleukin-2: inception, impact, and implications. Science 1988;240:1169-76.
8. Arcari P, Martinelli R, Salvatore F. The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: evidence for multiple mRNA species. Nucleic Acids Res 1984;12:9179-89.
9. Braakman E, Rotteveel FTM, van Bleek G, van Seventer GA, Lucas CJ. Are MHC class II-restricted cytotoxic T lymphocytes important? Immunol Today 1987;8:265-7.
10. + human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol 1984;133:754-7.
11. Yasukawa M, Zarling JM. Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens. J Immunol 1984;133:422-7.
12. + cytotoxic T lymphocyte clones. J Immunol 1982;129:2001-3.
13. + T lymphocytes in culture. Nature 1984;308:365-7.
14. Hayward A, Boylston A, Beverley P. Lysis of CD3 hybridoma targets by cloned human CD4 lymphocytes. Immunology 1988;64:87-92.
15. + cytotoxic T lymphocytes specific for T gondii-infected human melanoma cells. J Immunol 1995;154:290-8.
16. Vose BM, Bonnard GD. Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells. Nature 1982;296:359-61.
17. Hersey P, MacDonald M, Schibeci S, Burns C. Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma: classification based on phenotypes, specificity and inhibition by monoclonal antibodies to T cell structures. Cancer Immunol Immunother 1986;22:15-23.
18. Darrow TL, Slingluff CL, Seigler HF. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: evidence for shared tumor antigens. J Immunol 1989;142:3329-35.
19. Wölfel T, Klehmann E, Müller C, Schütt K-H, Meyer zum Büschenfelde K-H, Knuth A. Lysis of human melanoma cells by autologous cytolytic T cell clones: identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 1989;170:797-810.
20. Topalian SL, Soloman D, Rosenberg SA. Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 1989;142:3714-25.
21. Storkus WJ, Zeh III HJ, Maeurer MJ, Salter RD, Lotze MT. Identification of human melanoma peptides recognized by class I restricted tumor infiltrating T lymphocytes. J Immunol 1993;151:3719-27.
22. Kawakami Y, Zakut R, Topalian SL, Stötter H, Rosenberg SA. Shared human melanoma antigens: recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol 1992;148:638-43.
23. Hom SS, Topalian SL, Simonis T, Mancini M, Rosenberg SA. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction. J Immunother 1991;10:153-64.
24. + T-cell clones from regional lymph nodes of melanoma patients. Int J Cancer 1992;51:218-24.
25. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987;138:989-95.
26. + cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int J Cancer 1994;57:56-62.
27. Mochizuki M, Kuwabara T, McAllister C, Nussenblatt RB, Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 1985;26:1-9.
28. Atalla L, Linker-Israeli M, Steinman L, Rao NA. Inhibition of autoimmune uveitis by anti-CD4 antibody. Invest Ophthalmol Vis Sci 1990;31:1264-70.
29. McClellan KA, MacDonald M, Hersey P, Billson FA. Vogt-Koyanagi-Harada syndrome - isolation of cloned T cells with specificity for melanocytes and melanoma cells. Aust NZ J Ophthalmol 1989;17:347-52.
30. Wang X-c, Norose K, Yano A, Ohta K, Segawa K. Two-color flow cytometric analysis of activated T lymphocytes in aqueous humor of patients with endogenous vs exogenous uveitis. Curr Eye Res 1995;14:425-33.
31. Maezawa N, Yano A. Two distinct cytotoxic T lymphocyte subpopulations in patients with Vogt-Koyanagi-Harada disease that recognize human melanoma cells. Microbiol Immunol 1984;28:219-31.
32. + T cells. I. Involvement of the CD80-CD28 adhesion molecules. J Immunol 1995;155:118-27.
33. de Smet MD, Yamamoto JH, Mochizuki M, Gery I, Singh VK, Shinohara T, et al. Cellular immune responses of patients with uveitis to retinal antigens and their fragments. Am J Ophthalmol 1990;110:135-42.
34. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas: markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982;156:1755-66.
35. Hirose S, McAllister CG, Mittal KK, Vistica BP, Shinohara T, Gery I. A cell line and clones of lymphocytes from a healthy donor, with specificity to S-antigen. Invest Ophthalmol Vis Sci 1988;29:1636-41.
36. Skibber JM, Lotze MT, Uppenkamp I, Ross W, Rosenberg SA. Identification and expansion of human lymphokine-activated killer cells: implications for the immunotherapy of cancer. J Surg Res 1987;42:613-21.
37. Waard-Siebinga I de, Creyghton WM, Kool J, Jager MJ. Effects of interferon alfa and gamma on human uveal melanoma cells in vitro. Br J Ophthalmol 1995;79:847-55.
38. Yang T-H, Aosai F, Norose K, Ueda M, Yano A. Differential regulation of HLA-DR expression and antigen presentation in Toxoplasma gondii-infected melanoma cells by interleukin 6 and interferon γ. Microbiol Immunol 1996; 40:443-9.